IL-36 in psoriasis
Authors:
- Je SimsJSJe Sims
- 1 August 2012
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 12 (4) , 486-490
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) ActivityJournal of Biological Chemistry, 2011
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis PathogenesisJournal of Investigative Dermatology, 2011
- IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide ExpressionThe Journal of Immunology, 2011
- IL-1RL2 and Its Ligands Contribute to the Cytokine Network in PsoriasisThe Journal of Immunology, 2010
- The IL-1 family: regulators of immunityNature Reviews Immunology, 2010
- PsoriasisNew England Journal of Medicine, 2009
- Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammationJournal of Experimental Medicine, 2007
- Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-κB and MAPKsJournal of Biological Chemistry, 2004
- Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide arrayPhysiological Genomics, 2003
- Two Novel IL-1 Family Members, IL-1δ and IL-1ε, Function as an Antagonist and Agonist of NF-κB Activation Through the Orphan IL-1 Receptor-Related Protein 2The Journal of Immunology, 2001